The Argyrou's saw an opportunity to innovate in the crowded meal replacement market and the newly resourced company was oriented towards pursuing the development of nutrigenetic products and services.

Graeme Smith, a nutritional biochemist and biomedical researcher, was recruited to help formulate the meal replacement variants and develop accompanying genetically prescribed weight loss programs.

Further refinements to personalising diet included tests for genes associated with gluten sensitivity, lactose intolerance, salt palatability, appetite control, folate and Vitamin D metabolism.

[9][10][11] Dr. Ken Harvey, from the school of public health at La Trobe University challenged MyGene to provide evidence on the sensitivity and specificity of the tests being offered.

[12] With no response to the increasing number of questions being raised about MyGene's nutrigenetic test and a campaign by the Professional Pharmacists Australia association to have Pharmacy endorsement rescinded [13] the Weightloss Complete Genetic Program was withdrawn from the market during 2012.

In 2016, in a recapitulation of MyGene's contentious reception in the Australian market, the myDNA pharmacogenetic test [14] met with similar scepticism [15] regarding clinical utility and patient benefits.